Neuronetics, Inc.

STIM
About the company

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Country: United StatesPrice: $1.39Market Cap: $134.1M

Investment snapshot

12%positive consensus
Scored 1d ago

Positive

2

BUY / PASS

Neutral / negative

1 / 13

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 12 investors flag at least one debt & leverage criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2570 (Top 83%)PASSFAILFAILFAILFAILFAILFAILFAILPASSFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-17

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-17

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Debt & Leverage0% pass✓ 2✗ 13▾

      No clean pass — all 12 investors flag at least one debt & leverage criterion

      LT Debt vs Net Current AssetsLT Debt $61.8M vs NCA $27.0M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 3.30, IC: -1.7x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity3.30
      ✗Lynch< 0.33
      Cash - Long-term Debt$-39.6M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change39.14% -> 46.49%
      ✗PiotroskiDecreased YoY
      Current Assets / Current Liabilities2.01
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity3.30
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels3.30
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-1.7x, D/EBITDA=N/A
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity3.30
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-3.3008; #3957/4210 (top 94.0%)
      ✗AsnessTop 30% of eligible cross-section
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio4.3x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-8.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-8.6%, ROC=-185.0%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per Share4.3x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-37.7%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=-15.8%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=4.3x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Price vs. Trailing Low104% of trailing low ($1.34)
      ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-17.21%; #4470/6340 (top 70.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.1395; #4532/6449 (top 70.3%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+1.1913; #1587/5247 (top 30.2%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-7.15%; #3106/4519 (top 68.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+2.96%; #2303/6202 (top 37.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✓ 1✗ 11▾

      No clean pass — all 10 investors flag at least one cash flow criterion

      Free Cash Flow Proxy$-36.3M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-9.6M
      ✗LynchPositive and growing
      Operating Cash Flow$-20.4M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-14.39%, ROA=-27.55%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=-15.8%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/10 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-10.0%
      ✗Ackman>= 4%
      Price / FCF per ShareN/A (negative FCF)
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/10 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-9.6M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-7.15%; #3106/4519 (top 68.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Profitability6% pass✓ 5✗ 30▾

      15 of 16 flag STIM's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/11 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/11 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-104.4%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-21.1% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-36.3M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-123.4%
      ✗Lynch> 15%
      EBIT / Enterprise Value-8.6%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-8.6%, ROC=-185.0%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-27.55%
      ✗PiotroskiROA > 0
      ROA Change YoY-31.02% -> -27.55% (delta: +3.47%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-14.39%, ROA=-27.55%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY72.3% -> 48.5%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-123.4%
      ✗Dreman> 12%
      Margin of SafetyP/B=4.3x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-140.1% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-9.4%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-123.4%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-42.8% (2023) -> -21.1% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 72.5% -> 48.5%, operating margin -42.8% -> -21.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-17.21%; #4470/6340 (top 70.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+61.36%; #452/3702 (top 12.2%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity-123.36%; #4687/5226 (top 89.7%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0352; #2112/5884 (top 35.9%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Growth13% pass✓ 4✗ 9▾

      7 of 8 flag STIM's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: 14.4% vs Rev: 23.0%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/10 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth9.4%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 72.5% -> 48.5%, operating margin -42.8% -> -21.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR24.8%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Verdicts13% pass✓ 2✗ 14▾

      Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)✗GreenblattRank #2570✓PiotroskiPASS (F-Score 4)✗DremanFAIL (1/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (3/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1674/2370 (Top 70.6%))✗NeffFAIL (1/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Efficiency38% pass✓ 4✗ 7▾

      5 of 8 flag STIM's efficiency — Buffett, Greenblatt, Munger +2 more

      Current Ratio2.01
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-72.0%
      ✗Buffett> 10%
      ROIC - WACC-82.0%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-185.0%
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.86 -> 2.02
      ✓PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.53x -> 1.05x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities2.01
      ✓Dreman> 1.5
      Return on Invested Capital-14.7%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-25.8%; FY2024: ROIC=-33.0%; FY2025: ROIC=-28.2%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -28.2%)
      ✗SleepROIC > 12% in a majority of years

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($134.1M)
    Revenue: $149.2M+99.2% YoY
    Net Income: $39.0M+10.8% YoY

    Financial Snapshot

    Operating Margin-21.1%
    Return on Equity-174.3%
    Debt / Equity2.94
    Current Ratio2.02
    EPS (Diluted)$-0.59
    Shares Retired−24.4%

    Shareholder Return

    Fiscal 2025

    Issued 24.4% of shares last year.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-09-30

    2025-10-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, interest expense, operating cash flow, depreciation amortization, capex.

    Q3 FY 2026

    2026-07-01 – 2026-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-17
    FY 2024
    Sources
    • 10-K · 2026-03-17
    FY 2023
    Sources
    • 10-K · 2024-03-08
    FY 2022
    Sources
    • 10-K · 2023-03-07
    FY 2021
    Sources
    • 10-K · 2022-03-08
    Market Cap$134.1Mcurrent------$144.8Mest.$172.6Mest.$98.9Mest.$160.3Mest.$95.3Mest.
    Revenue$159.8M↑23%$42.0M↑13%$41.6M↑9%$34.5M↑8%$149.2M↑99%$74.9M↑5%$71.3M↑9%$65.2M↑18%$55.3M
    Operating Income-$15.0M↑60%$541.0K↑107%-$1.5M↑81%-$9.0M↑18%-$31.4M↑9%-$34.6M↓13%-$30.6M↑13%-$35.1M↓27%-$27.6M
    Net Income-$23.1M↑48%-$1.7M↑81%-$3.4M↑66%-$10.8M↑15%-$39.0M↑11%-$43.7M↓45%-$30.2M↑19%-$37.2M↓19%-$31.2M
    EPS (Diluted)--$-0.02↑85%$-0.05↑67%$-0.16↑24%$-0.59↑57%$-1.38↓31%$-1.05↑24%$-1.38↓13%$-1.22
    Gross Margin50.7%52.2%↑14%51.1%↑10%46.9%↓5%48.5%↓33%72.3%72.5%↓5%76.3%↓3%78.9%
    Operating Margin-9.4%↑68%1.3%↑107%-3.6%↑83%-26.1%↑24%-21.1%↑54%-46.2%↓8%-42.8%↑20%-53.8%↓8%-49.8%
    ROE-123.4%↑24%———-174.3%↓10%-157.8%↓79%-88.3%↓36%-65.1%↓78%-36.6%
    Total Debt$61.8M↓6%$61.8M↓6%$61.5M↑11%$61.3M↑11%$65.8M↑19%$55.2M↓7%$59.3M↑65%$36.0M↑2%$35.3M
    Shareholders' Equity$18.7M↓32%$18.7M↓32%$17.9M↓34%$13.3M↓63%$22.4M↓19%$27.7M↓19%$34.2M↓40%$57.1M↓33%$85.2M
    Current Ratio2.01↓11%2.01↓11%1.88↓7%1.67↓32%2.02↑8%1.86↓61%4.73↑59%2.98↓59%7.34
    Debt / Equity3.30↑37%3.30↑37%3.45↑68%4.62↑196%2.94↑48%1.99↑15%1.73↑175%0.63↑52%0.41
    Operating Cash Flow-$8.3M↑72%$1.2M↑258%-$1.0M↑71%-$9.4M↑45%-$20.4M↑34%-$31.0M↑3%-$32.0M↓4%-$30.7M↓10%-$28.0M
    Free Cash Flow-$9.6M↑69%$768.0K↑185%-$1.4M↑62%-$9.6M↑44%-$21.2M↑35%-$32.5M↑6%-$34.4M↓1%-$34.0M↓12%-$30.3M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    STIM vs Peers — Financial Grading

    Revenue$149.2MBottom 25%
    Net Income$39.0MBottom 25%
    ROE-174.3%Bottom 25%
    D/E2.94Bottom 25%
    Op. Margin-21.1%Bottom 25%
    Curr. Ratio2.02Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11